Boston-based Verve is a rare example of a gene editing company targeting a disease that affects a large population, offering ...

US Big Pharma firm Eli Lilly & Co. agreed to buy gene-editing biotech company Verve Therapeutics Inc. for $1.3 billion as the ...

Central Elementary School has released its honor roll for the fourth nine weeks and second semester of the 2024-2025 academic ...

The pending deal was rumored overnight after a report from the Financial Times, spurring analysts to speculate that if true, ...

Yum Brands named Chief Financial Officer Chris Turner as its next chief executive. Eli Lilly to Acquire Verve Therapeutics for Up to $1.3 Billion Deal would add a potential treatment for ...

In today's Pharmalittle roundup, we're reading about a Lilly deal, a gene therapy shock for Duchenne families, and more.

Eli Lilly's stock price has over-corrected following a downgrade in its outlook following the adjustment for acquisition ...

Meridian Dairy Days is just a few days away, and one of the most important events is the dairy goat and cattle shows that ...

Eli Lilly and Co. is shelling out $1 billion to buy a Boston biotech known for genetic medicines for cardiovascular disease.

Shares of Verve Therapeutics skyrocketed 75% in premarket trading Tuesday after Eli Lilly announced it would acquire the gene-editing startup for about $1.3 billion.

Verve Therapeutics’ stock rallies by a record 80% on Eli Lilly’s premium purchase price for the drug-development company.

The clearer the lakes, the greater the property values around them, Lilly Center for Lakes & Streams Director Dr. Nate Bosch ...